Molecular Changes in Myocardium in the Course of Anemia or Iron Deficiency

Heart Failure Clinics

Volumn 6, Issue 3, 2010, Pages 295-304

  Jankowska, Ewa A ^a   Ponikowski, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Anemia; Hemodynamics; Iron deficiency; Myocardium

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CASPASE 3; CYTOCHROME C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEMOGLOBIN; I KAPPA B; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; POTASSIUM CHANNEL; PROTEIN KINASE B; PROTEIN KINASE C; RAS PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VOLTAGE GATED CALCIUM CHANNEL;

ANEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HORMONE RELEASE; HORMONE RESISTANCE; HUMAN; IRON DEFICIENCY; IRON METABOLISM; MOLECULAR MECHANICS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; RISK FACTORS;

EID: 77953603162     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2010.03.003     Document Type: Review

References (114)

1. Somers K. Acute reversible heart failure in severe iron-deficiency anemia associated with hookworm infestation in Uganda Africans. Circulation 19 (1959) 672-675
2. Duke M., and Abelmann W.H. The hemodynamic response to chronic anemia. Circulation 39 (1969) 503-515
3. Silverberg D.S., Wexler D., Iaina A., et al. The role of correction of anemia in patients with congestive heart failure: a short review. Eur J Heart Fail 10 (2008) 819-823
4. Tang Y.D., and Katz S.D. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev 13 (2008) 387-392
5. Anand I.S., Kuskowski M.A., Rector T.S., et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112 (2005) 1121-1127
6. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 (2006) 1440-1446
7. Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 51 (2008) 569-576
8. Anand I.S. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev 13 (2008) 379-386
9. Manolis A.S., Tzeis S., Triantafyllou K., et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 355-375
10. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 1790 (2009) 682-693
11. Balla J., Jeney V., Varga Z., et al. Iron homeostasis in chronic inflammation. Acta Physiol Hung 94 (2007) 95-106
12. Anker S.D., Colet J.C., Filippatos G., et al. FAIR-HF committees and investigators. Rationale and design of Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anemia. Eur J Heart Fail 11 (2009) 1084-1091
13. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010, in press.
14. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97 (2000) 10526-10531
15. Scoppetta C., and Grassi F. Erythropoietin: a new tool for muscle disorders?. Med Hypotheses 63 (2004) 73-75
16. Noguchi C.T., Wang L., Rogers H.M., et al. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 10 (2008) e36
17. Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur Heart J 26 (2005) 2232-2237
18. van der Meer P., Voors A.A., Lipsic E., et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44 (2004) 63-67
19. George J., Patal S., Wexler D., et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165 (2005) 1304-1309
20. Iversen P.O., Woldbaek P.R., Tønnessen T., et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282 (2002) R166-R172
21. Li Y., Takemura G., Okada H., et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71 (2006) 684-694
22. van der Meer P., Lok D.J., Januzzi J.L., et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29 (2008) 1510-1515
23. Maiese K., Li F., and Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 293 (2005) 90-95
24. Lappin T.R., Maxwell A.P., and Johnston P.G. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 20 (2002) 485-492
25. Jelkmann W., and Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83 (2004) 673-686
26. Foley R.N. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 13 (2008) 405-414
27. Latini R., Brines M., and Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?. Heart Fail Rev 13 (2008) 415-423
28. Marzo F., Lavorgna A., Coluzzi G., et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 26 (2008) 183-187
29. van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 6 (2004) 853-859
30. Anagnostou A., Liu Z., Steiner M., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91 (1994) 3974-3978
31. Brines M., and Cerami A. Discovering erythropoietin's extrahematopoietic functions: biology and clinical promise. Kidney Int 70 (2006) 246-250
32. Depping R., Kawakami K., Ocker H., et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 130 (2005) 877-878
33. Lipsic E., Schoemaker R.G., van der Meer P., et al. Protective effects of erythropoietin in cardiac ischemia. J Am Coll Cardiol 48 (2006) 2161-2167
34. Parsa C.J., Kim J., Riel R.U., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279 (2004) 20655-20662
35. van der Meer P., Voors A.A., Lipsic E., et al. Erythropoietin in cardiovascular diseases. Eur Heart J 25 (2004) 285-291
36. Wu H., Lee S.H., Gao J., et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126 (1999) 3597-3605
37. Brines M., Grasso G., Fiordaliso F., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101 (2004) 14907-14912
38. Heidbreder M., Frohlich F., Johren O., et al. Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J 17 (2003) 1541-1543
39. Jung F., Palmer L.A., Zhou N., et al. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 86 (2000) 319-325
40. Toblli J.E., Cao G., Rivas C., et al. Heart and iron deficiency anemia in rats with renal insufficiency: the role of hepcidin. Nephrology (Carlton) 13 (2008) 636-645
41. Ryou M.G., Flaherty D.C., Hoxha B., et al. Pyruvate-fortified cardioplegia evokes myocardial erythropoietin signaling in swine undergoing cardiopulmonary bypass. Am J Physiol Heart Circ Physiol 297 (2009) H1914-1922
42. Smith K.J., Bleyer A.J., Little W.C., et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 59 (2003) 538-548
43. Ozaki K., and Leonard W.J. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 277 (2002) 29355-29358
44. D'Andrea A.D., and Zon L. Erythropoietin receptor. Subunit, structure and activation. J Clin Invest 86 (1990) 681-687
45. Baker J.E. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 42 (2005) 233-241
46. Farrell F., and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 Suppl 5 (2004) 18-30
47. Rafiee P., Shi Y., Su J., et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100 (2005) 187-197
48. Cai Z., and Semenza G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109 (2004) 2050-2053
49. Juhaszova M., Zorov D.B., Kim S.H., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113 (2004) 1535-1549
50. Shi Y., Rafiee P., Su J., et al. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 99 (2004) 173-182
51. Liu X., Xie W., Liu P., et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78 (2006) 2255-2264
52. Burger D., Lei M., Geoghegan-Morphet N., et al. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72 (2006) 51-59
53. Urao N., Okigaki M., Yamada H., et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 98 (2006) 1341-1343
54. Vanhoutte P.M. The endothelium modulator of vascular smooth-muscle tone. N Engl J Med 319 (1988) 512-513
55. Vallance P., Collier J., and Moncada S. Effects of endothelium derived nitric oxide on peripheral arteriolar tone in man. Lancet 2 (1989) 997-1000
56. Radomski M.W., Palmer R.M., and Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2 (1987) 1057-1058
57. Lindenblatt N., Menger M.D., Klar E., et al. Darbepoetin-alpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 27 (2007) 1191-1198
58. Dubey R.K., Jackson E.K., and Luscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells. Role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest 96 (1995) 141-149
59. Kubes P., Suzuki M., and Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88 (1991) 4651-4655
60. Ruschitzka F.T., Wenger R.H., Stallmach T., et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A 97 (2000) 11609-11613
61. Moon C., Krawczyk M., Ahn D., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100 (2003) 11612-11617
62. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
63. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
64. Tada H., Kagaya Y., Takeda M., et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res 71 (2006) 466-477
65. Fliser D., de Groot K., Bahlmann F.H., et al. Cardiovascular disease in renal patients-a matter of stem cells?. Nephrol Dial Transplant 19 (2004) 2952-2954
66. Bahlmann F.H., de Groot K., Haller H., et al. Erythropoietin: is it more than correcting anemia?. Nephrol Dial Transplant 19 (2004) 20-22
67. Bahlmann F.H., De Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
68. Bahlmann F.H., DeGroot K., Duckert T., et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64 (2003) 1648-1652
69. Mangi A.A., Noiseux N., Kong D., et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9 (2003) 1195-1201
70. Hamed S., Barshack I., Luboshits G., et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27 (2006) 1876-1883
71. Wald M., Gutnisky A., Borda E., et al. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Nephron 71 (1995) 190-196
72. Marrero M.B., Venema R.C., Ma H., et al. Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int 53 (1998) 1259-1268
73. Chong Z.Z., Kang J.Q., and Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22 (2002) 503-514
74. Carlini R.G., Alonzo E.J., Dominguez J., et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55 (1999) 546-553
75. Wizemann V., Kaufmann J., and Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 62 (1992) 161-165
76. Portoles J., Torralbo A., Martin P., et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29 (1997) 541-548
77. Palazzuoli A., Silverberg D.S., Calabrò A., et al. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol 53 (2009) 462-467
78. Palazzuoli A., Silverberg D.S., Iovine F., et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154 (2007) 645
79. Tramontano A.F., Muniyappa R., Black A.D., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308 (2003) 990-994
80. Lipsic E., Westenbrink B.D., van der Meer P., et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 10 (2008) 22-29
81. Moon C., Krawczyk M., Paik D., et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316 (2006) 999-1005
82. Fiordaliso F., Chimenti S., Staszewsky L., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102 (2005) 2046-2051
83. Fairbanks V., and Beutler E. Iron deficiency. In: Beutler E. (Ed). Williams hematology. 6th edition (2001), McGraw-Hill, New York 295-304 447-50
84. Dunn L.L., Rahmanto Y.S., and Richardson D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol 17 (2007) 93-100
85. Anderson G.J., and Vulpe C.D. Mammalian iron transport. Cell Mol Life Sci 66 (2009) 3241-3261
86. Cairo G., Bernuzzi F., and Recalcati S. A precious metal: iron, an essential nutrient for all cells. Genes Nutr 1 (2006) 25-39
87. Beard J.L. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 131 Suppl 2 (2001) 568S-579S
88. Sutak R., Lesuisse E., Tachezy J., et al. Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol 16 (2008) 261-268
89. Wilson M.T., and Reeder B.J. Oxygen-binding haem proteins. Exp Physiol 93 (2008) 128-132
90. Rouault T.A., and Tong W.H. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 6 (2005) 345-351
91. Gisbert J.P., and Gomollon F. An update on iron physiology. World J Gastroenterol 15 (2009) 4617-4626
92. Haas J.D., and Brownlie T. 4th. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 131 2S-2 (2001) 676S-690S
93. Anker S.D., Colet J.C., Filippatos G., et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009) 2436-2448
94. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51 (2008) 103-112
95. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107 (2003) 223-225
96. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48 (2006) 2485-2489
97. Handelman G.J., and Levin N.W. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13 (2008) 393-404
98. Kemna E.H., Tjalsma H., Willems H.L., et al. Hepcidin: from discovery to differential diagnosis. Haematologica 93 (2008) 90-97
99. Viatte L., and Vaulont S. Hepcidin, the iron watcher. Biochimie 91 (2009) 1223-1228
100. Suzuki H., Toba K., Kato K., et al. Serum hepcidin-20 is elevated during the acute phase of myocardial infarction. Tohoku J Exp Med 218 (2009) 93-98
101. Matsumoto M., Tsujino T., Lee-Kawabata M., et al. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J 74 (2010) 301-306
102. Merle U., Fein E., Gehrke S.G., et al. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 148 (2007) 2663-2668
103. Ge X.H., Wang Q., Qian Z.M., et al. The iron regulatory hormone hepcidin reduces ferroportin 1 content and iron release in H9C2 cardiomyocytes. J Nutr Biochem 20 (2009) 860-865
104. Qian Z.M., Chang Y.Z., Leung G., et al. Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim Biophys Acta 1772 (2007) 527-532
105. Isoda M, Hanawa H, Watanabe R, et al. Expression of the peptide hormone hepcidin increases in cardiomyocytes under myocarditis and myocardial infarction. J Nutr Biochem 2010, in press.
106. Turner L.R., Premo D.A., Gibbs B.J., et al. Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy. BMC Physiol 2 (2002) 1
107. Rossi M.A., and Carillo S.V. Electron microscopic study on the cardiac hypertrophy induced by iron deficiency anemia in the rat. Br J Exp Pathol 64 (1983) 373-387
108. Tanne Z., Coleman R., Nahir M., et al. Ultrastructural and cytochemical changes in the heart of iron-deficient rats. Biochem Pharmacol 47 (1994) 1759-1766
109. Olivetti G., Lagrasta C., Quaini F., et al. Capillary growth in anemia-induced ventricular wall remodeling in the rat heart. Circ Res 65 (1989) 1182-1192
110. Olivetti G., Quaini F., Lagrasta C., et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 141 (1992) 227-239
111. Medeiros D.M., and Beard J.L. Dietary iron deficiency results in cardiac eccentric hypertrophy in rats. Proc Soc Exp Biol Med 218 (1998) 370-375
112. Dong F., Zhang X., Culver B., et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci 109 (2005) 277-286
113. Chvapil M., Hurych J., and Ehrlichová E. The effect of iron deficiency on the synthesis of collagenous and non-collagenous proteins in wound granulation tissue and in the heart of rats. Exp Med Surg 26 (1968) 52-60
114. Naito Y., Tsujino T., Matsumoto M., et al. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296 (2009) H585-593